uniQure N.V. Investment Income, Interest
uniQure N.V. (QURE) reported Investment Income, Interest of $5.23 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-05-05
- uniQure N.V. investment income, interest for the quarter ending 2026-03-31 was $5.23M, a 26.70% increase year-over-year.
- uniQure N.V. investment income, interest for the quarter ending 2025-12-31 was $5.81M, a 37.23% increase year-over-year.
- uniQure N.V. investment income, interest for the quarter ending 2025-09-30 was $3.50M, a 28.01% decline year-over-year.
- uniQure N.V. investment income, interest for the quarter ending 2025-06-30 was $3.52M, a 39.29% decline year-over-year.
- uniQure N.V. investment income, interest for fiscal 2025 was $16.97M, a 20.77% decline from fiscal 2024.
- uniQure N.V. investment income, interest for fiscal 2024 was $21.41M, a 9.47% increase from fiscal 2023.
- uniQure N.V. investment income, interest for fiscal 2023 was $19.56M, a 3112.15% increase from fiscal 2022.
- uniQure N.V. investment income, interest for fiscal 2022 was $609.00K, a 275.93% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | $5.23M 10-Q · filed 2026-05-05 | $11.04M derived: sum of 2 quarters · filed 2026-05-05 | $14.54M derived: sum of 3 quarters · filed 2026-05-05 | $18.07M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.32M derived: sum of 2 quarters · filed 2026-03-02 | $12.84M derived: sum of 3 quarters · filed 2026-03-02 | $16.97M 10-K · filed 2026-03-02 |
| 2025-09-30 | $3.50M 10-Q · filed 2025-11-10 | $7.03M derived: sum of 2 quarters · filed 2025-11-10 | $11.15M 10-Q · filed 2025-11-10 | $15.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $3.52M 10-Q · filed 2025-07-29 | $7.65M 10-Q · filed 2025-07-29 | $11.89M derived: sum of 3 quarters · filed 2026-05-05 | $16.75M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $4.13M 10-Q · filed 2026-05-05 | $8.36M derived: sum of 2 quarters · filed 2026-05-05 | $13.23M derived: sum of 3 quarters · filed 2026-05-05 | $19.03M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.10M derived: sum of 2 quarters · filed 2026-03-02 | $14.91M derived: sum of 3 quarters · filed 2026-03-02 | $21.41M 10-K · filed 2026-03-02 |
| 2024-09-30 | $4.87M 10-Q · filed 2025-11-10 | $10.67M derived: sum of 2 quarters · filed 2025-11-10 | $17.18M 10-Q · filed 2025-11-10 | $24.35M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.80M 10-Q · filed 2025-07-29 | $12.31M 10-Q · filed 2025-07-29 | $19.48M derived: sum of 3 quarters · filed 2026-03-02 | $26.98M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $6.51M 10-Q · filed 2025-05-09 | $13.68M derived: sum of 2 quarters · filed 2026-03-02 | $21.17M derived: sum of 3 quarters · filed 2026-03-02 | $24.40M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $14.66M derived: sum of 2 quarters · filed 2026-03-02 | $17.89M derived: sum of 3 quarters · filed 2026-03-02 | $19.56M 10-K · filed 2026-03-02 |
| 2023-09-30 | $7.50M 10-Q · filed 2024-11-05 | $10.72M derived: sum of 2 quarters · filed 2024-11-05 | $12.39M 10-Q · filed 2024-11-05 | $12.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.23M 10-Q · filed 2024-08-01 | $4.90M 10-Q · filed 2024-08-01 | $5.39M derived: sum of 3 quarters · filed 2025-02-27 | $5.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-07 | $2.16M derived: sum of 2 quarters · filed 2025-02-27 | $2.20M derived: sum of 3 quarters · filed 2025-02-27 | $2.23M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $492.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $531.00K derived: sum of 2 quarters · filed 2025-02-27 | $566.00K derived: sum of 3 quarters · filed 2025-02-27 | $609.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $39.00K 10-Q · filed 2023-11-07 | $74.00K derived: sum of 2 quarters · filed 2023-11-07 | $117.00K 10-Q · filed 2023-11-07 | $155.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $35.00K 10-Q · filed 2023-08-01 | $78.00K 10-Q · filed 2023-08-01 | $116.00K derived: sum of 3 quarters · filed 2024-02-28 | $162.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $42.00K 10-Q · filed 2023-05-09 | $81.00K derived: sum of 2 quarters · filed 2024-02-28 | $127.00K derived: sum of 3 quarters · filed 2024-02-28 | $164.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $85.00K derived: sum of 2 quarters · filed 2024-02-28 | $122.00K derived: sum of 3 quarters · filed 2024-02-28 | $162.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | $46.00K 10-Q · filed 2022-11-02 | $83.00K derived: sum of 2 quarters · filed 2022-11-02 | $123.00K 10-Q · filed 2022-11-02 | $145.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $37.00K 10-Q · filed 2022-08-08 | $77.00K 10-Q · filed 2022-08-08 | $99.00K derived: sum of 3 quarters · filed 2023-02-27 | $112.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $40.00K 10-Q · filed 2022-05-02 | $62.00K derived: sum of 2 quarters · filed 2023-02-27 | $75.00K derived: sum of 3 quarters · filed 2023-02-27 | $156.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $35.00K derived: sum of 2 quarters · filed 2023-02-27 | $116.00K derived: sum of 3 quarters · filed 2023-02-27 | $938.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $13.00K 10-Q · filed 2021-10-25 | $94.00K derived: sum of 2 quarters · filed 2021-10-25 | $916.00K 10-Q · filed 2021-10-25 | $2.42M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $81.00K 10-Q · filed 2021-07-26 | $903.00K 10-Q · filed 2021-07-26 | $2.41M derived: sum of 3 quarters · filed 2022-02-25 | $3.28M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $822.00K 10-Q · filed 2021-05-10 | $2.33M derived: sum of 2 quarters · filed 2022-02-25 | $3.20M derived: sum of 3 quarters · filed 2022-02-25 | $3.93M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $2.38M derived: sum of 2 quarters · filed 2022-02-25 | $3.10M derived: sum of 3 quarters · filed 2022-02-25 | $3.55M 10-K · filed 2022-02-25 |
| 2019-09-30 | $868.00K 10-Q · filed 2020-10-27 | $1.60M derived: sum of 2 quarters · filed 2020-10-27 | $2.04M 10-Q · filed 2020-10-27 | $2.98M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $728.00K 10-Q · filed 2020-07-30 | $1.17M 10-Q · filed 2020-07-30 | $2.11M derived: sum of 3 quarters · filed 2021-03-01 | $3.06M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $442.00K 10-Q · filed 2020-04-29 | $1.39M derived: sum of 2 quarters · filed 2021-03-01 | $2.33M derived: sum of 3 quarters · filed 2021-03-01 | $2.92M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $944.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.89M derived: sum of 2 quarters · filed 2021-03-01 | $2.48M derived: sum of 3 quarters · filed 2021-03-01 | $2.73M 10-K · filed 2021-03-01 |
| 2018-09-30 | $949.00K 10-Q · filed 2019-10-28 | $1.53M derived: sum of 2 quarters · filed 2019-10-28 | $1.78M 10-Q · filed 2019-10-28 | $1.87M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $583.00K 10-Q · filed 2019-07-29 | $836.00K 10-Q · filed 2019-07-29 | $920.00K derived: sum of 3 quarters · filed 2020-03-02 | $930.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $253.00K 10-Q · filed 2019-04-29 | $337.00K derived: sum of 2 quarters · filed 2020-03-02 | $347.00K derived: sum of 3 quarters · filed 2020-03-02 | $359.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $94.00K derived: sum of 2 quarters · filed 2020-03-02 | $106.00K derived: sum of 3 quarters · filed 2020-03-02 | $117.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $10.00K 10-Q · filed 2018-11-06 | $22.00K derived: sum of 2 quarters · filed 2018-11-06 | $33.00K 10-Q · filed 2018-11-06 | $52.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $12.00K 10-Q · filed 2018-08-08 | $23.00K 10-Q · filed 2018-08-08 | $42.00K derived: sum of 3 quarters · filed 2019-02-28 | $56.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $11.00K 10-Q · filed 2018-04-30 | $30.00K derived: sum of 2 quarters · filed 2019-02-28 | $44.00K derived: sum of 3 quarters · filed 2019-02-28 | $59.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $33.00K derived: sum of 2 quarters · filed 2019-02-28 | $48.00K derived: sum of 3 quarters · filed 2019-02-28 | $70.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $14.00K 10-Q · filed 2017-11-01 | $29.00K derived: sum of 2 quarters · filed 2017-11-01 | $51.00K 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $15.00K 10-Q · filed 2017-08-08 | $37.00K 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $22.00K 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $121.00K 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $220.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |